Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study.

Schneeweiss S, Carver PL, Datta K, Galar A, Johnson MD, Johnson MG, Marty FM, Nagel J, Najdzinowicz M, Saul M, Shoham S, Silveira FP, Varughese CA, Wilck M, Weatherby L, Auton T, Walker AM.

J Antimicrob Chemother. 2016 Oct;71(10):2938-44. doi: 10.1093/jac/dkw225. Epub 2016 Jul 12.

PMID:
27407049
2.

Quinone oxidoreductase-2-mediated prodrug cancer therapy.

Middleton MR, Knox R, Cattell E, Oppermann U, Midgley R, Ali R, Auton T, Agarwal R, Anderson D, Sarker D, Judson I, Osawa T, Spanswick VJ, Davies S, Hartley JA, Kerr DJ.

Sci Transl Med. 2010 Jul 14;2(40):40ra50. doi: 10.1126/scitranslmed.3000615.

3.
4.

Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects.

Brown MJ, Coltart J, Gunewardena K, Ritter JM, Auton TR, Glover JF.

Clin Sci (Lond). 2004 Aug;107(2):167-73.

PMID:
15040783
5.

Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man.

Downham MR, Auton TR, Rosul A, Sharp HL, Sjöström L, Rushton A, Richards JP, Mant TG, Gardiner SM, Bennett T, Glover JF.

Br J Clin Pharmacol. 2003 Nov;56(5):505-12.

6.

Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats.

Gardiner SM, Auton TR, Downham MR, Sharp HL, Kemp PA, March JE, Martin H, Morgan PJ, Rushton A, Bennett T, Glover JF.

Br J Pharmacol. 2000 Mar;129(6):1178-82.

8.

From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug.

Lock EA, Ellis MK, Gaskin P, Robinson M, Auton TR, Provan WM, Smith LL, Prisbylla MP, Mutter LC, Lee DL.

J Inherit Metab Dis. 1998 Aug;21(5):498-506. Review.

PMID:
9728330
9.

Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes.

Eldridge MD, Murray CW, Auton TR, Paolini GV, Mee RP.

J Comput Aided Mol Des. 1997 Sep;11(5):425-45.

PMID:
9385547
10.

PRO_SELECT: combining structure-based drug design and combinatorial chemistry for rapid lead discovery. 1. Technology.

Murray CW, Clark DE, Auton TR, Firth MA, Li J, Sykes RA, Waszkowycz B, Westhead DR, Young SC.

J Comput Aided Mol Des. 1997 Mar;11(2):193-207.

PMID:
9089436
11.
12.
13.

Characterization of the interaction of 2-[2-nitro-4-(trifluoromethyl)benzoyl]-4,4,6,6,-tetramethyl- cyclohexane-1,3,5-trione with rat hepatic 4-hydroxyphenylpyruvate dioxygenase.

Ellis MK, Whitfield AC, Gowans LA, Auton TR, Provan WM, Lock EA, Lee DL, Smith LL.

Chem Res Toxicol. 1996 Jan-Feb;9(1):24-27.

PMID:
8924597
14.

Thresholds in chemical carcinogenesis.

Purchase IF, Auton TR.

Regul Toxicol Pharmacol. 1995 Dec;22(3):199-205.

PMID:
8837843
15.
16.

Retrospective appraisal of the relationship between skin irritancy and contact sensitization potential.

Auton TR, Botham PA, Kimber I.

J Toxicol Environ Health. 1995 Oct;46(2):149-54.

PMID:
7563214
17.

Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione.

Ellis MK, Whitfield AC, Gowans LA, Auton TR, Provan WM, Lock EA, Smith LL.

Toxicol Appl Pharmacol. 1995 Jul;133(1):12-9.

PMID:
7597701
18.

Vehicle effects on in vitro percutaneous absorption through rat and human skin.

Hilton J, Woollen BH, Scott RC, Auton TR, Trebilcock KL, Wilks MF.

Pharm Res. 1994 Oct;11(10):1396-400.

PMID:
7855041
19.
20.

Calculation of benchmark doses from teratology data.

Auton TR.

Regul Toxicol Pharmacol. 1994 Apr;19(2):152-67.

PMID:
8041913
21.

A physiologically based mathematical model of dermal absorption in man.

Auton TR, Westhead DR, Woollen BH, Scott RC, Wilks MF.

Hum Exp Toxicol. 1994 Jan;13(1):51-60.

PMID:
8198830
22.
23.

Modelling dermal pharmacokinetics using in vitro data. Part II. Fluazifop-butyl in man.

Auton TR, Ramsey JD, Woollen BH.

Hum Exp Toxicol. 1993 May;12(3):207-13.

PMID:
8100431
24.

Modelling dermal pharmacokinetics using in vitro data. Part I. Fluazifop-butyl in the rat.

Auton TR, Ramsey JD, Woollen BH.

Hum Exp Toxicol. 1993 May;12(3):199-206.

PMID:
8100430
25.

Pharmacokinetics of fluazifop-butyl in human volunteers. II: Dermal dosing.

Ramsey JD, Woollen BH, Auton TR, Batten PL, Leeser JE.

Hum Exp Toxicol. 1992 Jul;11(4):247-54.

PMID:
1354971
26.

Human inhalation pharmacokinetics of chlorodifluoromethane (HCFC22).

Woollen BH, Marsh JR, Mahler JD, Auton TR, Makepeace D, Cocker J, Blain PG.

Int Arch Occup Environ Health. 1992;64(5):383-7.

PMID:
1487335
27.

Joint risk from multiple compound exposure.

Auton TR.

Risk Anal. 1991 Jun;11(2):181-5. No abstract available.

PMID:
1876719
28.
29.

Human inhalation pharmacokinetics of 1,1,2-trichloro-1,2,2-trifluoroethane (FC113).

Woollen BH, Guest EA, Howe W, Marsh JR, Wilson HK, Auton TR, Blain PG.

Int Arch Occup Environ Health. 1990;62(1):73-8.

PMID:
2295526

Supplemental Content

Support Center